知网在线教学  
录播课程 中成药热毒宁注射液抗新冠肺炎相关基础及临床研究进展/Progress in Preclinical and Clinical Research on Reduning Injection in Treatment of COVID-19
综合评分5.0 浏览4750 收藏22
课程概述 课程目录 相关资料 课后作业 学习讨论 课程评价(0)

1. 演讲题目/Topic

    中成药热毒宁注射液抗新冠肺炎相关基础及临床研究进展

    Progress in Preclinical and Clinical Research on Reduning Injection in Treatment of COVID-19

 

    公益播放期间,本课程浏览和学习达到188人次。

    During public welfare period, this lecture has attracted 188 visitors and learners.

 

2. 演讲语言/Language

    中文语音&英文字幕/Chinese voice & English subtitles

 

3. 演讲嘉宾/Lecturer

       曹亮,男,高级工程师,主要从事新药开发研究。先后获得新药临床和生产批件10项;申请国内外专利84件,35件获得授权;在核心期刊上发表论文100余篇,其中SCI27篇。曾获得国家科学技术进步二等奖等国家、省部级奖励多项。
       Cao Liang, senior engineer, is mainly engaged in the development of new drugs. He has successively obtained good manufacturing practices (GMP) certificates from the National Medical Products Administration (NMPA) for 10 new TCM drugs. As the major inventor, he has filed 84 patents, 35 of which have been authorized. He has also published more than 100 papers in core journals, including 27 recorded by SCI. He has won multiple national and provincial awards, such as the National Science and Technology Progress Award.

 

4. 演讲内容/Abstract

       热毒宁注射液是获得中国专利金奖的中药新药,由青蒿、金银花、栀子组成,临床用于呼吸道病毒感染性疾病的治疗,新冠疫情爆发期间完成了治疗新冠肺炎基础及多中心临床研究,临床研究显示可显著缩短患者临床症状痊愈时间,缩短核酸转阴时间、住院时间,提高痊愈率,改善血液学指标,降低重症转化。

       Reduning Injection, composed of Herba Artemisiae Annuae, Flos Lonicerae, and Fructus Gardeniae, is applicable to the treatment of viral respiratory infections. After the outbreak of coronavirus disease 2019 (COVID-19) in China, a randomized, open-labeled, multi-center, controlled trial was conducted to explore the efficacy of Reduning Injection in the treatment of COVID-19. The results showed that Reduning Injection shortened the median time to resolution of the clinical symptoms, reduced the time required for nucleic acid test turning negative and hospital stay, increased the recovery rate, improved hematological indices, and decreased the deterioration rate.



推荐电子书/Recommended e-books:

     

双语版/Bilingual editionhttp://jtp.cnki.net/bilingual/EBook/Detail?pykm=TCMC

中文版/Chinese editionhttps://book.oversea.cnki.net/CCGBWEB/Book/Detail/OB200803001

英文版/English editionhttps://book.oversea.cnki.net/CCGBWEB/Book/Detail/OB200803002


       权威的主编和编委:主编为中国工程院院士、中国中医科学院院长黄璐琦,17位编委为来自中国科学院、中国中医科学院等机构的教授、研究员,以及三甲医院的主任医师。

       Distinguished Editor-in-Chief and editorial board membersEditor-in-Chief HUANG Luqi is the academician of Chinese Academy of Engineering and president of China Academy of Chinese Medical Sciences. The Editorial Board includes 17 professors and chief physicians from Chinese Academy of Sciences, China Academy of Chinese Medical Sciences, and first-class hospitals in China.


       严格的质量把关:由中华中医药学会和国家中医药管理局科技司组织专家从首发在中国知网(CNKI)的中医药抗击COVID-19的近800篇论文中精选70篇进行双语出版。

       Strict quality controlAll 70 papers are strictly selected from nearly 800 online-first papers about COVID-19 treatment with TCM by the experts organized by China Association of Chinese Medicine and National Administration of Tradition Chinese Medicine.


       一流的学术成果:报道一线疗效显著的最新临床实践内容。病例涉及各级分型,多年龄层及地域,并兼顾多种并发症。治疗手段包含中药、针灸、中西医结合等。对世界范围内抗击COVID-19的临床实践具有普遍的指导意义。

       Authoritative resources of anti-epidemic achievements by TCMThe papers involve the latest TCM clinical practice in the first-line treatments, cover various COVID-19 cases, age groups, regions, and complications, and include different effective TCM treatments. They possess universal guiding significance to clinical treatment of COVID-19 worldwide.


电子书可在网站注册下单或联系销售人员订购/Place your order on website or contact with our sales managers

marketing@int.cnki.net

beijing@cnki.net


综合评分 5.0
我们是来自中国知网科技双语出版中心的团队,是目前中国知网第一支,也是唯一一支科技领域中英双语出版的团队。产品涉及基础科学、工程技术、农业科学、医药卫生、环境生态... 更多
相关课程 更多
  • 回放
    从病毒的精准检测到肿瘤的精准医疗
    中国生物工程学会
    2020/05/11 14:50
  • 回放
    互联网医院带来的医疗服务创新
    中日友好医院毛发中...
    2020/07/21 19:00
  • 回放
    头皮健康管理
    中日友好医院毛发中...
    2020/07/24 18:30
  • 回放
    男性雄激素性秃发治疗进展
    中日友好医院毛发中...
    2020/07/28 19:00